Bioteke Corporation (Wuxi) Co., Ltd. appears in FDA device records as the applicant for a single 510(k) clearance in the collection reviewed here, K261409, decided 2026-09-10. The filing covers the BioTeke® Multi-Drug Urine Test Cup under product code NFT and regulation 862.3100, with Clinical Toxicology as the review panel. The manufacturer’s own product pages describe a fixed 14-panel urine drug test cup and a second product line of molecular reagents. The record set does not establish ownership, headquarters, customers or commercial volumes. [1][3][8]
The K261409 filing and its scope
FDA records list K261409 as a Traditional 510(k) received 2026-04-30 and decided 2026-09-10 with decision code SESE, substantially equivalent. The device is the BioTeke® Multi-Drug Urine Test Cup, classified as a Class II amphetamine over-the-counter test under 21 CFR 862.3100, product code NFT, in the Clinical Toxicology advisory committee. The submission carried a summary rather than a full statement, and the third-party review flag is N. [1][8]
The applicant address on the filing is in Wuxi, Jiangsu, China, with Zhitu Zhou listed as contact. That address is a filing detail, not a verified corporate headquarters. The collection reviewed here contains one linked 510(k) record, and its decision count shows one SESE outcome; the smaller record sample likewise holds that single entry. These counts describe the retrieved filings only and say nothing about total portfolio size or safety performance. [1][8]
Product identity and configuration
The manufacturer’s product page describes the BioTeke Multi-Drug Urine Test Cup as qualitative screening for 14 drugs and drug metabolites in human urine, labeled for in vitro diagnostic use and prescription use only, and states that results are preliminary and require confirmation. The page references the K261409 clearance and directs distributors to the panel, cut-off concentrations and supporting documentation. [3]
A separate distributor-facing page describes a fixed 14-analyte panel and invites review of the cut-off table and instructions before selection. A GUDID record for primary DI 06974541566049 lists brand BioTeke, model 1 Test/kit, catalog number ICA2506-14, prescription status true, over-the-counter status false, single use true, sterile false, and in commercial distribution, published 2026-10-13. That record carries product codes NFT and NFV. [7][9]
Company description and other product lines
BioTeke’s own news item announces the K261409 clearance, published 2026-09-11, and describes the company as operating two complementary product lines under one quality system: laboratory-grade molecular reagents and point-of-care rapid tests, serving laboratories and distributors in more than 100 countries. Those statements are the manufacturer’s characterization of its business, not independently verified findings. [6]
The same description appears on the distributor page for the urine test cup. Neither page identifies a parent company, subsidiary structure or brand owner beyond Bioteke Corporation (Wuxi) Co., Ltd., so any relationship to other entities remains unknown. [6][7]
Clinical laboratory categorization
A CLIA database result tied to document number K261409 lists a moderate-complexity entry for tricyclic antidepressants under Toxicology / TDM, dated 09/30/2026, alongside a separate document number CR260360. The result page reports 14 matching results for the document number search. This categorization is a laboratory regulatory classification and does not describe test performance. [5]
